Source: Eur Respir J 2015; 46: 1636-1644
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
de Boer J. Daan, Berger Marieke, Majoor Christof J., Kager Liesbeth M., Meijers Joost C.M., Terpstra Sanne, Nieuwland Rienk, Boing Anita N., Lutter René, Wouters Diana, Mierlo Gerard J. van, Zeerleder Sacha S., Bel Elisabeth H., Veer Cornelis van't, Vos Alex F. de, Zee Jaring S. van der, Poll Tom van der. Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial. Eur Respir J 2015; 46: 1636-1644

Member's Comments

No comment yet.

Related content which might interest you: A randomized double-blind study of specific immunotherapy (SIT) in patients with seasonal allergic rhinitis: effects on clinical and inflammatory markers Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001 Activated protein C inhibits bronchial inflammation and hyperresponsiveness in a mouse model of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002 Neutrophil activation in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 400s Year: 2003 LSC - 2019 - Anti-IL5 in mild asthma alters rhinovirus-induced macrophage, B cell and neutrophil responses Source: International Congress 2019 – Novel mechanisms elucidated by translational studies of asthma Year: 2019 LSC 2010 Abstract: Creatine supplementation upregulates chronic allergic airway inflammation and remodeling via activation of epithelial cells Source: Annual Congress 2010 - COPD and asthma: models and human studies Year: 2010 Platelet depletion abolishes neutrophil recruitment in non-allergic murine models of acute inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 760s Year: 2006 CXCL-8-dependent and -independent neutrophil activation in COPD: experiences from a pilot study of the CXCR2 antagonist danirixin Source: ERJ Open Res, 6 (4) 00583-2020; 10.1183/23120541.00583-2020 Year: 2020 Relative sensitivity of markers of activated eosinophils in clinical trials for asthma Source: Annual Congress 2010 - Induced sputum in relation: a fresh look on phenotyping and monitoring Year: 2010 Late Breaking Abstract: A randomised, placebo controlled trial of 6 weeks‘ treatment with a novel oral p38 inhibitor in patients with COPD Source: Annual Congress 2010 - COPD: management Year: 2010 Treatment: how does inflammatory phenotype influence response to treatment in airway disease? Source: Annual Congress 2007 - Inflammatory phenotypes in airway disease Year: 2007 PBF-680, an oral A1 adenosine receptor antagonist, inhibits the late allergic response (LAR) in mild-to-moderate atopic asthmatics: a Phase-IIa trial Source: Virtual Congress 2020 – Cutting edge science: novel molecules and mechanisms of airway diseases Year: 2020 Levofloxacin prevents eosinophil activation and asthma exacerbation Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006 Late Breaking Abstract - Phase 2 trial evaluating the effects of dexpramipexole on blood eosinophils, lung function, and airway biomarkers in eosinophilic asthma Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Changes in eosinophil count and C reactive protein following treatment with mebendazole in patients with Toxocara-associated asthma Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Lower incidence of asthma exacerbations with FENO-guided anti-inflammatory treatment: A randomised controlled trial Source: Annual Congress 2012 - Effectiveness of respiratory disease management in primary care Year: 2012 Neutrophil to lymphocyte ratio and severity of COPD : prospective study Source: Virtual Congress 2021 – New insights into the airway immunology of lung disease Year: 2021 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Does eosinophil cationic protein (ECP) predict asthma outcome and response to treatment in asthmatic patients? Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012